Status:
COMPLETED
Study of ZIO-101 in Multiple Myeloma
Lead Sponsor:
Alaunos Therapeutics
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Eligibility Criteria
Inclusion
- Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00303199
Start Date
January 1 2006
End Date
August 1 2007
Last Update
July 19 2012
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States
2
West Hollywood, California, United States
3
Miami, Florida, United States
4
Bethesda, Maryland, United States